查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917737

血清学检测市场－2026-2031年预测

Serological Testing Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计血清学检测市场将从 2025 年的 61.14 亿美元成长到 2031 年的 87.27 亿美元，复合年增长率为 6.11%。

血清学检测市场是现代诊断医学的关键组成部分，它透过分析血液样本中特定的抗体、抗原和其他免疫标记物，为免疫反应提供重要资讯。这些检测对于多种应用至关重要，包括诊断感染疾病、评估免疫状态（疫苗接种后或感染后）、检测自体免疫疾病以及监测慢性病。该行业服务于广泛的终端用户网络，主要包括医院、临床检查室、血库和公共卫生机构，所有这些机构都依赖血清学检测的准确性和可靠性来进行病患管理、血液安全和流行病学监测。全球医疗保健环境持续存在的结构性趋势推动了市场成长。

主要市场成长要素

市场扩张得益于多个强劲且持续的驱动因素。主要成长要素是全球医疗基础设施的持续扩张和完善，特别是新建医院和诊断检查室。随着医疗网路服务范围的扩大，诊断检测量自然也会增加。血清学检测是医院检查室诊断肝炎、爱滋病、莱姆病和德国麻疹等疾病的基础检测方法，也可用于术前筛检和一般健康评估。这种基础设施的成长直接转化为对可靠的检测试剂、设备和平台的需求增加。

与此密切相关的是血库服务的策略性扩张和现代化。血清学检测是输血安全的重要基础，所有捐血的血液都必须接受输血传染病（如爱滋病毒、B型肝炎、C型肝炎和梅毒）的强制性筛检。在监管要求和公共卫生优先事项的双重推动下，全球为确保血液供应安全所做的努力，正在持续且显着地推动对筛检检测的需求。增加自愿捐血和建立区域血液处理中心的倡议，进一步推动了这项需求。

此外，公共卫生措施和流行病学调查计画的增加是成长要素。各国政府和国际卫生组织越来越多地利用指南检测进行人群层面的研究，例如监测疾病流行情况、评估群体免疫力、指导疫苗宣传活动以及应对疫情。血清学检测能够识别先前感染，使其成为公共卫生规划和资源分配的强大工具，有助于购买用于大规模筛检的检测试剂。

区域展望：亚太优势

亚太地区预计将引领全球血清学检测市场。这一主导地位源于该地区庞大且不断增长的人口，以及对医疗基础设施的快速且大规模的投资。该地区许多国家正积极扩大医院网络，提升检测能力，并实施包括广泛诊断筛检在内的国家卫生计画。政府主导的旨在改善公共卫生状况、控制感染疾病和保障血液安全的各项倡议，持续推动对诊断检测的显着需求，使亚太地区成为市场成长的关键驱动力。

主要市场限制因素

限制更广泛、更公平的市场进入的主要阻碍因素是先进血清学检测的高成本，包括自动化分析仪、专用试剂组和复杂的多重检测等相关费用。在资源匮乏的环境中，例如发展中地区和医疗资源不足的医疗系统，这些成本可能构成障碍。高昂的检测成本会限制常规使用，阻碍最新检测技术的普及，并造成诊断能力的缺口。这种经济障碍使得价格敏感型细分市场的渗透更加复杂，因此亟需开发更具成本效益的解决方案，同时又不影响必要的准确性。

竞争格局与策略趋势

该市场以大规模体外诊断（IVD）公司为特征，这些公司提供全面的仪器、试剂和软体产品组合。主要企业在检测准确性、灵敏度和特异性、检测专案广度、自动化能力以及与实验室资讯系统的整合等方面展开竞争。竞争格局强调检测形式的持续创新，包括用于核心检查室的高通量自动化系统和用于分散式环境的快速就地检验。

产业相关人员的策略重点领域包括：拓展检测项目以涵盖新发和再发病原体；提升自动化程度以提高检查室效率并减少人为错误；以及开发可从单一检体中检测多种分析物的多重检测方法，从而节省时间和资源。在关键市场获得监管部门核准、建立强大的分销商网络以及为检查室客户提供可靠的技术支持，对于成功至关重要。

未来发展与策略考量

受医疗基础设施、血液安全和公共卫生等领域非週期性需求的推动，血清学检测市场预计将持续成长。未来发展趋势将受到以下因素的影响：个人化医疗的趋势、对新兴感染疾病威胁快速反应的需求，以及将血清学数据与其他诊断方法相结合以进行更全面的患者评估。

产业领导者的策略重点包括：应对复杂多变的监管环境；为高通量参考实验室和资源匮乏地区开发分级产品系列；以及投资研发，将新型生物标记发现转化为经临床检验的检测方法。作为诊断、筛检和监测的基础工具，血清学检测仍然是临床和公共卫生实践的重要组成部分，其市场成长与全球扩大和改善医疗服务的努力密不可分。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略进入市场的可能性。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用洞察力并做出策略决策，在动态环境中开发新的业务流和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的实际数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 按检测类型分類的血清学检测市场

  • 介绍
  • 初筛血清学检测
    • 酵素免疫分析法（ELISA）
    • 萤光抗体测定（IFAT）
    • 免疫测量（RIA）
  • 二级血清学
    • 凝集反应
    • 补体结合试验（CFT）
    • 沉淀反应
  • 血清中和试验（SNT）
    • 毒素-抗毒素检测
    • 三级结合试验

6. 按应用分類的血清学检测市场

  • 介绍
  • 轮状病毒
  • 肝炎
  • HIV
  • 内毒素
  • 治疗药物监测
  • 其他感染疾病

7. 依最终用户分類的血清学检测市场

  • 介绍
  • 医院和诊所
  • 诊断检查室
  • 血库
  • 其他的

8. 各地区血清学检测市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • 英国血清学研究所（SERI）
  • Chembio Diagnostics, Inc.（美国）
  • Cellex（美国）
  • 朗道实验室有限公司（英国）
  • 雅培（美国）
  • Bio-Rad Laboratories Inc.（美国）
  • BD（美国）
  • 赛默飞世尔科技公司（美国）
  • Ortho Clinical Diagnostics（美国）
  • Quest Diagnostics Incorporated（美国）

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615692

The serological testing market is expected to grow at a 6.11% CAGR, achieving USD 8.727 billion in 2031 from USD 6.114 billion in 2025.

The serological testing market is a critical component of modern diagnostic medicine, providing essential insights into immune response through the analysis of blood samples for specific antibodies, antigens, and other immunological markers. These tests are indispensable for a wide range of applications, including the diagnosis of infectious diseases, assessment of immune status (post-vaccination or post-infection), autoimmune disease detection, and monitoring of chronic conditions. The industry serves a broad network of end-users, primarily hospitals, clinical laboratories, blood banks, and public health agencies, all of which rely on the accuracy and reliability of serological assays for patient management, blood safety, and epidemiological surveillance. Market growth is fueled by enduring structural trends within the global healthcare landscape.

Primary Market Growth Drivers

Market expansion is underpinned by several powerful and sustained drivers. A fundamental catalyst is the ongoing global expansion and strengthening of healthcare infrastructure, particularly the establishment of new hospitals and diagnostic laboratories. As healthcare networks grow to serve larger populations, the volume of diagnostic testing inherently increases. Serological tests are a staple in hospital laboratories for diagnosing conditions like hepatitis, HIV, Lyme disease, and rubella, as well as for pre-operative screenings and general health assessments. This infrastructure growth directly translates to higher demand for reliable testing reagents, instruments, and platforms.

Closely linked is the strategic expansion and modernization of blood bank services. Serological testing is a non-negotiable pillar of blood safety, mandated for screening all donated blood for transfusion-transmissible infections such as HIV, hepatitis B and C, and syphilis. The global emphasis on ensuring a safe blood supply, driven by both regulatory mandates and public health priorities, creates a consistent, high-volume demand for serological screening assays. Initiatives to increase voluntary blood donations and establish regional blood processing centers further bolster this demand.

Furthermore, the increase in public health initiatives and epidemiological surveillance programs is a significant growth vector. Governments and international health organizations increasingly utilize serological testing for population-level studies to monitor disease prevalence, assess herd immunity, guide vaccination campaigns, and manage outbreak responses. The ability of serology to identify past infections makes it a powerful tool for public health planning and resource allocation, driving procurement of tests for large-scale screening efforts.

Geographical Outlook: Asia-Pacific Dominance

The Asia-Pacific region is estimated to dominate the global serological testing market. This projected leadership is attributed to the region's massive and growing population, coupled with rapid and large-scale investments in healthcare infrastructure. Many countries in the region are actively expanding their hospital networks, upgrading laboratory capabilities, and implementing national health programs that include widespread diagnostic screening. Government-led initiatives aimed at improving public health outcomes, controlling infectious diseases, and ensuring blood safety are creating a sustained and high-volume demand for diagnostic tests, positioning Asia-Pacific as the primary engine for market growth.

Key Market Restraint

A significant restraint on broader and more equitable market access is the high cost associated with advanced serological testing. This includes expenses related to automated analyzers, proprietary reagent kits, and sophisticated multiplex assays. In resource-constrained settings, including developing regions and underfunded healthcare systems, these costs can be prohibitive. High test costs can limit routine use, restrict access to the latest testing technologies, and create disparities in diagnostic capabilities. This economic barrier challenges market penetration in price-sensitive segments and necessitates the development of more cost-effective solutions without compromising essential accuracy.

Competitive Landscape and Strategic Dynamics

The market is characterized by the presence of large, multinational in-vitro diagnostics (IVD) corporations that offer comprehensive portfolios of instruments, reagents, and software. Key players compete on the basis of assay accuracy, sensitivity and specificity, test menu breadth, automation capabilities, and integration into laboratory information systems. The competitive landscape emphasizes continuous innovation in assay formats, including the development of high-throughput automated systems for core laboratory use and rapid point-of-care tests for decentralized settings.

Strategic focus areas for industry participants include expanding test menus to cover emerging and re-emerging pathogens, improving automation to enhance laboratory efficiency and reduce human error, and developing multiplex assays that can detect multiple analytes from a single sample to conserve time and resources. Success depends on securing regulatory approvals across key markets, establishing strong distributor networks, and providing robust technical support to laboratory customers.

Future Trajectory and Strategic Considerations

The serological testing market is poised for sustained growth, driven by the non-cyclical needs of healthcare infrastructure, blood safety, and public health. Future developments will likely be influenced by trends toward more personalized medicine, the need for rapid response to emerging infectious disease threats, and the integration of serological data with other diagnostic modalities for a more holistic patient assessment.

For industry leaders, strategic priorities will include navigating complex and evolving regulatory pathways, developing tiered product portfolios to serve both high-throughput reference labs and low-resource settings, and investing in research to translate new biomarker discoveries into clinically validated assays. As a fundamental tool for diagnosis, screening, and surveillance, serological testing will remain an indispensable element of clinical and public health practice, with its market growth inextricably linked to the global commitment to expanding and improving healthcare delivery.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Serological Testing Market Segmentation

  • By Test Type
  • Primary Serological Tests
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Immunofluorescent Antibody Technique (IFAT)
  • Radio Immunoassay (RIA)
  • Secondary Serological Tests
  • Agglutination Tests
  • Complement Fixation Tests (CFT)
  • Precipitation Tests
  • Serum Neutralization Tests (SNT)
  • Toxin-antitoxin Tests
  • Tertiary Binding Tests
  • By Application
  • Rotavirus
  • Hepatitis
  • HIV
  • Endotoxins
  • Therapeutic Drug Monitoring
  • Other Infectious Diseases
  • By End-User
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Blood Banks
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SEROLOGICAL TESTING MARKET BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Primary Serological Tests
    • 5.2.1. Enzyme Linked Immunosorbent Assay (ELISA)
    • 5.2.2. Immunofluorescent Antibody Technique (IFAT)
    • 5.2.3. Radio Immunoassay (RIA)
  • 5.3. Secondary Serological Tests
    • 5.3.1. Agglutination Tests
    • 5.3.2. Complement Fixation Tests (CFT)
    • 5.3.3. Precipitation Tests
  • 5.4. Serum Neutralization Tests (SNT)
    • 5.4.1. Toxin-antitoxin Tests
    • 5.4.2. Tertiary Binding Tests

6. SEROLOGICAL TESTING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Rotavirus
  • 6.3. Hepatitis
  • 6.4. HIV
  • 6.5. Endotoxins
  • 6.6. Therapeutic Drug Monitoring
  • 6.7. Other Infectious Diseases

7. SEROLOGICAL TESTING MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Diagnostic Laboratories
  • 7.4. Blood Banks
  • 7.5. Others

8. SEROLOGICAL TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Serological Research Institute (SERI) (U.K.)
  • 10.2. Chembio Diagnostics, Inc (U.S.)
  • 10.3. Cellex (U.S.)
  • 10.4. Randox Laboratories Ltd (U.K.)
  • 10.5. Abbott (U.S.)
  • 10.6. Bio-Rad Laboratories Inc. (U.S.)
  • 10.7. BD (U.S.)
  • 10.8. Thermo Fisher Scientific Inc. (U.S.)
  • 10.9. Ortho Clinical Diagnostics (U.S.)
  • 10.10. Quest Diagnostics Incorporated (U.S.)

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations